Inhibition of cisplatin-induced lipid catabolism and weight loss by ghrelin in male mice

Endocrinology

Volumn 154, Issue 9, 2013, Pages 3118-3129

  Garcia, Jose M ^a   Scherer, Thomas ^b,d   Chen, Ji An ^a,f   Guillory, Bobby ^a   Nassif, Anriada ^c   Papusha, Victor ^a   Smiechowska, Joanna ^a   Asnicar, Mark ^a   Buettner, Christoph ^b   Smith, Roy G ^a,e  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GHRELIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CACHEXIA; FATTY ACID OXIDATION; FOOD INTAKE; LIPID METABOLISM; LIPOGENESIS; LIPOLYSIS; LIVER; MALE; MOUSE; MUSCLE; NONHUMAN; PRIORITY JOURNAL; WEIGHT; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE;

ADIPOSE TISSUE, WHITE; ADIPOSITY; ANIMALS; ANTINEOPLASTIC AGENTS; APPETITE STIMULANTS; BIOLOGICAL MARKERS; CACHEXIA; CISPLATIN; ENERGY INTAKE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GHRELIN; LIPOGENESIS; LIPOLYSIS; LIVER; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; RANDOM ALLOCATION; WEIGHT LOSS;

EID: 84883197539     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1179     Document Type: Article

References (42)

1. Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care. 2005;8(3):265-269.
2. Maltoni M, Nanni O, Pirovano M, et al. Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care. J Pain Symptom Manage. 1999;17(4):240-247.
3. Agustsson T, Rydén M, Hoffstedt J, et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res. 2007;67(11):5531-5537.
4. Rydén M, Agustsson T, Laurencikiene J, et al. Lipolysis-not inflammation, cell death, or lipogenesis-is involved in adipose tissue loss in cancer cachexia. Cancer. 2008;113(7):1695-1704.
5. Das SK, Eder S, Schauer S, et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science. 2011;333(6039):233-238.
6. Jeevanandam M, Horowitz GD, Lowry SF, Brennan MF. Cancer cachexia and the rate of whole body lipolysis in man. Metabolism. 1986;35(4):304-310.
7. Verstappen CC, Heimans JJ, Hoekman K, Postma TJ. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs. 2003;63(15):1549-1563.
8. Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407(6806):908-913.
9. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature. 2001;409:194-198.
10. MurphyMG, Plunkett LM, Gertz BJ, et al. MK-677, an orally active growth hormone secretagogue reverses diet-induced catabolism. J Clin Endocrinol Metab. 1998;83:320-325.
11. Strassburg S, Anker SD, Castaneda TR, et al. Long-term effects of ghrelin and ghrelin receptor agonists on energy balance in rats.AmJ Physiol Endocrinol Metab. 2008;295(1):E78-E84.
12. Wisse BE, Frayo RS, Schwartz MW, Cummings DE. Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology. 2001;142(8):3292-3301.
13. Nagaya N, Kangawa K. Ghrelin improves left ventricular dysfunction and cardiac cachexia in heart failure. Curr Opin Pharmacol. 2003;3(2):146-151.
14. Garcia JM, Garcia-Touza M, Hijazi RA, et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab. 2005;90(5):2920-2926.
15. Sawhney P, Giammona CJ, Meistrich ML, Richburg JH. Cisplatininduced long-term failure of spermatogenesis in adult C57/Bl/6J mice. J Androl. 2005;26(1):136-145.
16. Seaman F, Sawhney P, Giammona CJ, Richburg JH. Cisplatin-induced pulse of germ cell apoptosis precedes long-term elevated apoptotic rates in C57/BL/6 mouse testis. Apoptosis. 2003;8(1):101-108.
17. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966; 50(4):219-244.
18. Hiura Y, Takiguchi S, Yamamoto K, et al. Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study. Cancer. 2012;118(19):4785-4794.
19. Sun Y, Wang P, Zheng H, Smith RG. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci USA. 2004; 101(13):4679-4684.
20. Shen WJ, Sridhar K, Bernlohr DA, Kraemer FB. Interaction of rat hormone-sensitive lipase with adipocyte lipid-binding protein. Proc Natl Acad Sci USA. 1999;96(10):5528-5532.
21. Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009; 9(4):327-338.
22. Buettner C, Muse ED, Cheng A, et al. Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat Med. 2008;14(6):667-675.
23. AnthonsenMW,Rö nnstrand L, Wernstedt C, Degerman E,HolmC. Identification of novel phosphorylation sites in hormone-sensitive lipase that are phosphorylated in response to isoproterenol and govern activation properties in vitro. J Biol Chem. 1998;273(1):215-221.
24. Greenberg AS, Shen WJ, Muliro K, et al. Stimulation of lipolysis and hormone-sensitive lipase via the extracellular signal-regulated kinase pathway. J Biol Chem. 2001;276(48):45456-45461.
25. Bartness TJ, Shrestha YB, Vaughan CH, Schwartz GJ, Song CK. Sensory and sympathetic nervous system control of white adipose tissue lipolysis. Mol Cell Endocrinol. 2010;318(1-2):34-43.
26. Muoio DM, Newgard CB. Fatty acid oxidation and insulin action: when less is more. Diabetes. 2008;57(6):1455-1456.
27. Garcia JM, Cata JP, Dougherty PM, Smith RG. Ghrelin prevents cisplatin-induced mechanical hyperalgesia and cachexia. Endocrinology. 2008;149(2):455-460.
28. Deboer MD, Zhu X, Levasseur PR, et al. Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology. 2008;149(2):827-835.
29. Yakabi K, Sadakane C, Noguchi M, et al. Reduced ghrelin secretion in the hypothalamus of rats due to cisplatin-induced anorexia. Endocrinology. 2010; 15198):3773-3782
30. Hiura Y, Takiguchi S, Yamamoto K, et al. Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients. Int J Clin Oncol. 2012;17(4):316-323.
31. Dobrzyn P, Dobrzyn A, Miyazaki M, et al. Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. Proc Natl Acad SciUSA. 2004;101(17): 6409-6414.
32. Theander-Carrillo C, Wiedmer P, Cettour-Rose P, et al. Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest. 2006;116(7):1983-1993.
33. Barazzoni R, Bosutti A, Stebel M, et al. Ghrelin regulates mitochondrial-lipid metabolism gene expression and tissue fat distribution in liver and skeletal muscle. Am J Physiol Endocrinol Metab. 2005; 288(1):E228-E235.
34. Wang W, Andersson M, Iresjö BM, Lö nnroth C, Lundholm K. Effects of ghrelin on anorexia in tumor-bearing mice with eicosanoidrelated cachexia. Int J Oncol. 2006;28(6):1393-1400.
35. Davies JS, Kotokorpi P, Eccles SR, et al. Ghrelin induces abdominal obesity via GHS-R-dependent lipid retention. Mol Endocrinol. 2009;23(6):914-924.
36. Barazzoni R, Semolic A, Cattin MR, Zanetti M, Guarnieri G. Acylated ghrelin limits fat accumulation and improves redox state and inflammation markers in the liver of high-fat-fed rats [published online March 20, 2013]. Obesity (Silver Spring). doi: 10.1002/oby.20454.
37. Porporato PE, Filigheddu N, Reano S, et al. Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. J Clin Invest. 2013; 123(2):611-622.
38. Liu W, Thomas SG, Asa SL, Gonzalez-Cadavid N, Bhasin S, Ezzat S. Myostatin is a skeletal muscle target of growth hormone anabolic action. J Clin Endocrinol Metab. 2003;88(11):5490-5496.
39. Cao H, Gerhold K, Mayers JR, Wiest MM, Watkins SM, Hotamisligil GS. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell. 2008;134(6):933-944.
40. Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr Diab Rep. 2006;6(3):177-181.
41. Funai K, Semenkovich CF. Skeletal muscle lipid flux: running water carries no poison. Am J Physiol Endocrinol Metab. 2011;301(2): E245-E251.
42. ThidarMyint H, Yoshida H, Ito T, Kuwayama H. Dose-dependent response of plasma ghrelin and growth hormone concentrations to bovine ghrelin in Holstein heifers. J Endocrinol. 2006;189(3):655-664